Somnus Scientific - ProSed Propofol Monitoring

Helping a MedTech company understand clinical challenges and market opportunities in the UK

Clinical Background
Somnus Scientific developed ProSed, a near-patient rapid propofol monitor designed to personalise and optimise sedation in Intensive Care Units (ICUs). It aims to improve patient outcomes while reducing the burden on healthcare professionals and NHS resources. Following initial exploration of the UK and American markets, the company is preparing for a UK launch in 2026 and USA in 2027.

Clinical Challenge
Ahead of its UK launch, the company needed a deeper understanding of current NHS practices in sedation monitoring, particularly those involving propofol, and how ProSed could improve patient care.

With funding from InnovateUK, Somnus chose Medipex to expand their clinical insight, support economic modelling and shape a compelling value proposition for NHS organisations.

How Medipex Helped
Medipex conducted a comprehensive review of sedation practices in NHS ICUs and sedation-reliant invasive procedures. This included:

Assessing the current implementation of national clinical guidance on sedation monitoring
Identifying key gaps in current ICU sedation practices, especially in propofol use
Highlighting associated organisational and workforce pressures
Evaluating the downstream impact on patient safety and staff wellbeing
The findings informed aspects of the economic model developed by a Market Access Expert partner, helping quantify ProSed's potential value at NHS Trust level.

These insights are now contributing to the company’s UK launch strategy and pilot planning.

Client Testimonial

“Medipex supported us in scaling the market opportunity and provided a strong foundation for the Cost Consequence model.”

“Medipex were accessible and responsive, with effective support provided through online meetings.”

“Medipex also uncovered valuable market intelligence and data sources that we were previously unaware of.”